Safety of a killed oral cholera vaccine (Shanchol) in pregnant women in Malawi: an observational cohort study.

Autor:	Ali M; Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. Electronic address: mali25@jhu.edu., Nelson A; Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA., Luquero FJ; Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA., Azman AS; Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA., Debes AK; Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA., M'bang'ombe MM; Epidemiological Unit, Ministry of Health, Lilongwe, Malawi., Seyama L; Johns Hopkins Project, Blantyre, Malawi., Kachale E; Johns Hopkins Project, Blantyre, Malawi., Zuze K; Johns Hopkins Project, Blantyre, Malawi., Malichi D; Johns Hopkins Project, Blantyre, Malawi., Zulu F; Johns Hopkins Project, Blantyre, Malawi., Msyamboza KP; World Health Organization, Malawi Country Office, Lilongwe, Malawi., Kabuluzi S; Preventive Health Services Department, Ministry of Health, Lilongwe, Malawi., Sack DA; Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Jazyk:	angličtina
Zdroj:	The Lancet. Infectious diseases [Lancet Infect Dis] 2017 May; Vol. 17 (5), pp. 538-544. Date of Electronic Publication: 2017 Feb 02.
DOI:	10.1016/S1473-3099(16)30523-0
Abstrakt:	Background: Pregnancy increases the risk of harmful effects from cholera for both mothers and their fetuses. A killed oral cholera vaccine, Shanchol (Shantha Biotechnics, Hydrabad, India), can protect against the disease for up to 5 years. However, cholera vaccination campaigns have often excluded pregnant women because of insufficient safety data for use during pregnancy. We did an observational cohort study to assess the safety of Shanchol during pregnancy. Methods: This observational cohort study was done in two adjacent districts (Nsanje and Chikwawa) in Malawi. Individuals older than 1 year in Nsanje were offered oral cholera vaccine during a mass vaccination campaign between March 30 and April 30, 2015, but no vaccines were administered in Chikwawa. We enrolled women who were exposed to oral cholera vaccine during pregnancy in Nsanje district, and women who were pregnant in Chikwawa district (and thus not exposed to oral cholera vaccine) during the same period. The primary endpoint of our analysis was pregnancy loss (spontaneous miscarriage or stillbirth), and the secondary endpoints were neonatal deaths and malformations. We evaluated these endpoints using log-binomial regression, adjusting for the imbalanced baseline characteristics between the groups. This study is registered with ClinicalTrials.gov, number NCT02499172. Findings: We recruited 900 women exposed to oral cholera vaccine and 899 women not exposed to the vaccine between June 16 and Oct 10, 2015, and analysed 835 in each group. 361 women exposed to the vaccine and 327 not exposed to the vaccine were recruited after their pregnancies had ended. The incidence of pregnancy loss was 27·54 (95% CI 18·41-41·23) per 1000 pregnancies among those exposed to the vaccine and 21·56 (13·65-34·04) per 1000 among those not exposed. The adjusted relative risk for pregnancy loss among those exposed to oral cholera vaccine was 1·24 (95% CI 0·64-2·43; p=0·52) compared with those not exposed to the vaccine. The neonatal mortality rate was 11·78 (95% CI 5·92-23·46) per 1000 livebirths for infants whose mothers were exposed to oral cholera vaccine versus 8·91 (4·02-19·77) per 1000 livebirths for infants whose mothers were not exposed to the vaccine (crude relative risk 1·32, 95% CI 0·46-3·84; p=0·60). Only three newborn babies had malformations, two in the vaccine exposure group and one in the no-exposure group, yielding a relative risk of 2·00 (95% CI 0·18-22·04; p=0·57), although this estimate is unreliable because of the small number of outcomes. Interpretation: Our study provides evidence that fetal exposure to oral cholera vaccine confers no significantly increased risk of pregnancy loss, neonatal mortality, or malformation. These data, along with findings from two retrospective studies, support use of oral cholera vaccine in pregnant women in cholera-affected regions. Funding: Bill & Melinda Gates Foundation. (Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license. Published by Elsevier Ltd.. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu